B+
Bull case
25%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
MYGN
Myriad GeneticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Cancer Care Continuum growth and new product launches could offset weakness in Prenatal Health if reimbursement initiatives stabilize average revenue per test. Management also identified multiple 2027 growth drivers [#SEC-8K-2026-07-30].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.5.
What can break
Adjusted EBITDA guidance is suspended while Ascend implementation costs and benefits remain uncertain.
Momentum
2
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.25 · Bull $5.00 · Bear $2.10Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $3.37
Why
Momentum2 · Δ7d +0.4
Value41 · Δ7d 0.0
Sentiment69 · Δ7d +6.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.5.
Contradictions & invalidation
- • Adjusted EBITDA guidance is suspended while Ascend implementation costs and benefits remain uncertain.
- • Available liquidity was approximately $190 million, but the packet does not establish a definitive cash-runway outlook.
- • The Q2 miss exposed weaker prenatal volumes, hereditary-cancer payer friction, lower reimbursement, and uncertain efficiency-program economics.
Catalyst clock
2026-11-02
Ascend efficiency and revenue-cycle execution
Lead driver: Sentiment · See AI snapshot
Momentum
2
9% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
69
62% active weight
Current posture
7d trendImproving
Δ7d
+6.5
Δ21d
-12.6
Why this grade
Composite grade C. Momentum 2.2 / Value 41.2 / Sentiment 69.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$291.73M
Beta
1.90
Shares Out
95.65M
P/E (TTM) · Derived
-0.8
P/S (TTM)
0.69
P/FCF (TTM) · Derived
-40.61
Rev YoY
-10.5%
EPS YoY
-87.2%
Gross Margin
+65.1%
Op Margin
-11.2%
Net Debt
$60.2M
Current Ratio
2.21
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data